GAO Zhuo 1 , TIAN Chen 2,3,4 , ZHENG Qingyong 3,5 , LI Yimeng 2 , HAN Siyu 2 , TIAN Jinhui 3,5 , GE Long 2,3,4
  • 1. School of Nursing, Gansu University of Chinese Medicine, Lanzhou 730000, P. R. China;
  • 2. Department of Health Policy and Management, School of Public Health, Lanzhou University, Lanzhou 730000, P. R. China;
  • 3. Key Laboratory of Evidence Based Medicine of Gansu Province, Lanzhou 730000, P. R. China;
  • 4. Evidence-Based Social Science Research Center, School of Public Health, Lanzhou University, Lanzhou 730000, P. R. China;
  • 5. Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou 730000, P. R. China;
GE Long, Email: gelong2009@163.com
Export PDF Favorites Scan Get Citation

Living systematic reviews (LSR) represent an evolving methodology for systematic review that is continuously updated to incorporate new evidence in a timely manner, ensuring that healthcare professionals and policymaker shave access to the most last information to make optimal decisions. The global publication of LSR has been a rapid increase. But the quality of reporting remains to be enhanced. In 2024, the PRISMA-LSR working group, in conjunction with the characteristics of LSR to form the reporting standards for living systematic reviews, which plays a significant role in promoting the transparent, complete, and accurate reporting of LSR. It has been published in the BMJ journal. This article interpreted PRISMA-LSR with representative examples, aiming to provide a reference for the standardization of LSR by domestic scholars.

Citation: GAO Zhuo, TIAN Chen, ZHENG Qingyong, LI Yimeng, HAN Siyu, TIAN Jinhui, GE Long. Interpretation of the preferred reporting items for living systematic reviews and meta-analyses (PRISMA-LSR). Chinese Journal of Evidence-Based Medicine, 2025, 25(7): 856-863. doi: 10.7507/1672-2531.202412093 Copy

Copyright © the editorial department of Chinese Journal of Evidence-Based Medicine of West China Medical Publisher. All rights reserved

  • Previous Article

    Current status and considerations of Data Monitoring Committee (DMC) reports in clinical trials introduction
  • Next Article

    Interpretation of the 2024 international consensus: recommendations for empagliflozin in the treatment of neutropenia and neutrophil dysfunction associated with glycogen storage disease type Ib